An Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Amikacin/fosfomycin (Primary)
- Indications Bronchitis; Pneumonia
- Focus Pharmacokinetics
- Sponsors Cardeas Pharma
- 08 Jul 2016 Status changed from recruiting to completed.
- 09 May 2016 Status changed from not yet recruiting to recruiting.
- 18 Mar 2016 New trial record